These data demonstrate the novel finding that a liposome formulation designed to target PAK-1 and Group IIA sPLA2 demonstrated increased efficacy against TNBC cells as compared to cells derived from non-metastatic breast cancer tissues. Here, PAK1 is linked to breast cancer.